J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)
Mary Akosile,Sherry Pierce,Mark Brandt,Srdan Verstovsek,Gautam Borthakur,Hagop M. Kantarjian,Farhad Ravandi,William G. Wierda,Guillermo Garcia-Manero,Naval Daver,Tapan M. Kadia,Jan A. Burger,Naveen Pemmaraju,Elias Jabbour,Jorge E. Cortes +14 more
TL;DR: The impact of sequential TKI therapy, although standard practice, has not been well studied and pt's characteristics, response to therapy, transformation to accelerated and blast phase, and long term outcomes are analyzed.
Journal Article
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))
Peter Hillmen,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Nancy L. Bartlett,Jianyong Li,D. Simpson,Sebastian Grosicki,S. Devereux,Helen McCarthy,S. E. Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,A Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,A Pollack,Constantine S. Tam,Deepali Suri,Cathy Zhou,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps,Jan A. Burger +33 more
TL;DR: A randomized, open-label phase 3 trial to evaluate efficacy and safety of single-agent ibr vs clb in treatment-naive older pts with CLL/SLL found that ibr reduced the risk of progression or death by 91% and was consistent within subgroups including age ≥70 years, del11q, and unmutated IGHV .
Journal ArticleDOI
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Wei Liu,Jan A. Burger,Jie Xu,Zhenya Tang,Gokce Altay Toruner,Mahsa Khanlari,L. Jeffrey Medeiros,Guilin Tang +7 more
TL;DR: It is suggested that LPL deletion might be utilized as a biomarker for risk stratification and to predict therapeutic response in this high-risk group of CLL patients.
Journal ArticleDOI
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
Farhad Ravandi,Susan O'Brien,Rebecca Garris,Stefan Faderl,Deborah A. Thomas,Jan A. Burger,Alessandra Ferrajoli,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian +9 more
TL;DR: This phase II trial determined the long-term efficacy of the combination of the hyperCVAD regimen with dasatinib for treating patients with Ph+ ALL and found that 45 patients have achieved complete molecular remission (CMR) and another 19 have achieved a major (but not complete) molecular response (MMR).
Journal ArticleDOI
Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).
Stefan Faderl,Deborah A. Thomas,Varsha Gandhi,Gautam Borthakur,Xuelin Huang,William Plunkett,Jan A. Burger,Jorge E. Cortes,Susan O'Brien,Farhad Ravandi,Jennie Bretz,Monica Kwari,Hagop M. Kantarjian +12 more
TL;DR: Although no MTD has been defined yet and accrual continues in cohort 2, it appears unlikely that the MTD will exceed the dose levels of cohort 2.